European Organisation For Research & Treatment Of Cancer
Efecto de la inmunoterapia en pacientes con cáncer de pulmón de células no pequeñas oligometastásico (número limitado de metástasis) después de haber sido tratados con radioterapia y/o cirugía
- Conditions
- Non-small cell lung cancer
- First Posted Date
- 2024-10-07
- Last Posted Date
- 2025-01-08
- Target Recruit Count
- 142
- Registration Number
- 2023-508741-40-00
- Locations
- 🇫🇷
Institut Paoli Calmettes, Marseille, France
🇫🇷GIE Groupe hospitalier Paris Saint-Joseph/Vinci, Paris Cedex 14, France
🇫🇷Centre Hospitalier De La Cote Basque, Bayonne, France
Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors
- Conditions
- Prostate Cancer
- Interventions
- Drug: iMABDrug: cMAB
- First Posted Date
- 2023-08-03
- Last Posted Date
- 2025-03-18
- Target Recruit Count
- 1600
- Registration Number
- NCT05974774
Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study
- Conditions
- First Progression of Glioblastoma
- Interventions
- Radiation: Reirradiation
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2025-06-23
- Target Recruit Count
- 411
- Registration Number
- NCT05904119
- Locations
- 🇮🇹
Azienda ospedaliero Univ Policlinico Umberto I, Roma, Italy
🇳🇱ETZ Tilburg - ETZ - St. Elisabethziekenhuis, Tilburg, Netherlands
🇦🇹A.O Landeskrankenhaus - Innsbruck Universitaetsklinik, Innsbruck, Austria
Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer
- Conditions
- Oligometastatic Squamous Cell Carcinoma of the Head and Neck
- Interventions
- Radiation: stereotattic ablation radiotherapy (SABR)
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2025-06-23
- Target Recruit Count
- 200
- Registration Number
- NCT05815927
- Locations
- 🇧🇪
Cliniques Universitaires Saint-Luc, Brussels, Belgium
🇧🇪AZ Groeninge Kortrijk - Campus Kennedylaan, Kortrijk, Belgium
🇧🇪CHU-UCL Namur - CHU Site Sainte-Elisabeth-UCL Namur, Namur, Belgium
Radiotherapy Plus Xevinapant in Older Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma
- Conditions
- Locally Advanced Head and Neck Squamous Cell Carcinoma
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-02-13
- Last Posted Date
- 2024-08-27
- Target Recruit Count
- 230
- Registration Number
- NCT05724602
- Locations
- 🇧🇪
Onze Lieve Vrouw Ziekenhuis, Aalst, Belgium
🇧🇪Universitair Ziekenhuis Gent, Gent, Belgium
🇧🇪Cliniques Universitaires Saint-Luc, Woluwe-Saint-Lambert, Belgium
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)
- Conditions
- HER2-negative Breast CancerStage IIB Breast CancerStage III Breast CancerER-positive Breast Cancer
- Interventions
- First Posted Date
- 2022-08-23
- Last Posted Date
- 2024-01-24
- Target Recruit Count
- 220
- Registration Number
- NCT05512364
- Locations
- 🇧🇪
Institut Jules Bordet, Anderlecht, Belgium
🇧🇪AZ KLINA Brasschaat, Brasschaat, Belgium
🇧🇪Cliniques Universitaires Saint-Luc, Brussels, Belgium
Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification
- Conditions
- Embryonal TumorGliomaChoroid Plexus TumorTumor of the Sellar RegionPineal TumorMelanocytic Tumor of CNSPineal TumorsHemangiopericytomaGlioneuronal TumorGerm Cell Tumor
- First Posted Date
- 2022-02-28
- Last Posted Date
- 2025-01-03
- Target Recruit Count
- 1250
- Registration Number
- NCT05259605
- Locations
- 🇩🇪
Universitaetsklinikum Bonn, Bonn, Germany
🇬🇧NHS Lothian - The Royal Infirmary Of Edinburgh, Edinburgh, United Kingdom
🇦🇹Innsbruck Universitaetsklinik, Innsbruck, Austria
Chemo-free BRCA-targeted Neoadjuvant Strategy
- Conditions
- BRCA2 MutationTNBC - Triple-Negative Breast CancerBRCA1 Mutation
- Interventions
Dissecting the Pathways of Therapy Resistance in Early Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2021-08-09
- Last Posted Date
- 2024-02-22
- Target Recruit Count
- 31
- Registration Number
- NCT04995575
- Locations
- 🇧🇪
Onze Lieve Vrouw Ziekenhuis, Aalst, Belgium
🇧🇪Institut Jules Bordet-Hopital Universitaire ULB, Brussels, Belgium
🇧🇪Hopital De Jolimont, Haine-Saint-Paul, Belgium
Phase II Trial of Romiplostim for Thrombocytopenia Induced by Lomustine at First Progression of MGMT Promoter-meth Glioblastoma
- Conditions
- First Progression of MGMT Promoter-methylated Glioblastoma
- Interventions
- Locations
- 🇪🇸
Hospital Clinic Universitari de Barcelona, Barcelona, Spain
🇪🇸Hospital Universitario Ramon y Cajal, Madrid, Spain
🇪🇸Hospital Universitario 12 De Octubre, Madrid, Spain